FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC
Published on 28 January 2026
Dr Caio Rocha Lima speaks to ecancer about the phase III COMMIT trial, combining atezolizumab with FOLFOXIRI plus bevacizumab significantly improved outcomes compared with atezolizumab alone in treatment-naïve dMMR/MSI-H metastatic colorectal cancer.
Dr Rocha Lima highlights that at interim analysis, FFX/bev + atezolizumab reduced the risk of progression by 56% (HR 0.44; P=0.0103), with a median PFS of 30.0 months versus 4.3 months for atezolizumab monotherapy.
Objective response and disease control rates were also substantially higher with the combination, though with increased grade ≥3 adverse events.
Dr Rocha Lima concludes by saying that these results support dual immunotherapy and VEGF inhibition with chemotherapy as a more effective frontline strategy in dMMR/MSI-H mCRC.